Author

Antonio Russo

University of Palermo - Cited by 19,309 - Oncology

Biography

Dr. Antonio Russo is an Associate professor in the department of Surgical and Oncological Sciences, Section of Medical Oncology, University of Palermo, Italy. His study interests major on Oncology, medical surgery. In recent years, he has studied tumors, genetics. Currently, Dr. Russo is the author/editors/reviewer in several international journals. He published 11 articles in many journals and the articles are informative and got good citations.
Title
Cited by
Year
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
G Badalamenti, D Fanale, L Incorvaia, N Barraco, A Listi, R Maragliano, ...Cellular immunology 343, 103753, 2019201
197
2019
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
F Passiglia, G Bronte, V Bazan, C Natoli, S Rizzo, A Galvano, A Listì, ...Oncotarget 7 (15), 19738, 2016201
155
2016
Circular RNA in exosomes
V Fanale, D., Taverna, S., Russo, A., BazanAdvances in Experimental Medicine and Biology, 2018149201
149
2018
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
V Silvestri, D Barrowdale, AM Mulligan, SL Neuhausen, S Fox, BY Karlan, ...Breast Cancer Research 18, 1-13, 2016201
127
2016
Increased interictal visual network connectivity in patients with migraine with aura
G Tedeschi, A Russo, F Conte, D Corbo, G Caiazzo, A Giordano, ...Cephalalgia 36 (2), 139-147, 2016201
108
2016
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis
F Passiglia, G Bronte, V Bazan, A Galvano, B Vincenzi, A RussoCritical reviews in oncology/hematology 99, 150-157, 2016201
94
2016
Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond
D Di Lisi, R Madonna, C Zito, E Bronte, G Badalamenti, P Parrella, I Monte, ...International journal of cardiology 227, 11-17, 2017201
78
2017
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
F Passiglia, F., Rizzo, S., Maio, M., Galvano, A., Badalamenti, G., Listì, A ...Scientific Reports, 2018201
77
2018
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
D Massihnia, A Avan, N Funel, M Maftouh, A Van Krieken, C Granchi, ...Journal of Hematology & Oncology 10, 1-17, 2017201
75
2017
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ...The Lancet Oncology 19 (4), 4-485, 2018201
74
2018
Targeting angiogenesis in biliary tract cancers: An open option
V Simone, O Brunetti, L Lupo, M Testini, E Maiorano, M Simone, V Longo, ...International journal of molecular sciences 18 (2), 418, 2017201
58
2017
Relationship between anxiety level and radiological investigation. Comparison among different diagnostic imaging exams in a prospective single-center study
G Lo Re, R De Luca, F Muscarneri, P Dorangricchia, D Picone, ...La radiologia medica 121, 763-768, 2016201
48
2016
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection
DL Banna, G.L., Passiglia, F., Colonese, F., Canova, S., Menis, J., Addeo, A ...Critical Reviews in Oncology/Hematology, 2018201
44
2018
Risk Perception and Psychological Distress in Genetic Counselling for Hereditary Breast and/or Ovarian Cancer
A Cicero, G., De Luca, R., Dorangricchia, P., Lo Coco, G., Guarnaccia, C ...Journal of Genetic Counseling, 2017201
42
2017
The Era of PARP inhibitors in ovarian cancer:“Class Action” or not? A systematic review and meta-analysis
N Staropoli, D Ciliberto, T Del Giudice, E Iuliano, M Cucè, F Grillone, ...Critical Reviews in Oncology/Hematology 131, 83-89, 2018201
41
2018
Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions
M Fioramonti, D Santini, M Iuliani, G Ribelli, P Manca, N Papapietro, ...Oncotarget 8 (12), 20113, 2017201
38
2017
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus
D Cabibi, S Caruso, V Bazan, M Castiglia, G Bronte, S Ingrao, D Fanale, ...Oncotarget 7 (30), 47821, 2016201
37
2016
Whole‐exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene
V Silvestri, V Zelli, V Valentini, P Rizzolo, AS Navazio, A Coppa, S Agata, ...Cancer 123 (2), 210-218, 2017201
36
2017
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors
E Bronte, G Bronte, G Novo, G Rinaldi, F Bronte, F Passiglia, A RussoPharmacology & therapeutics 192, 65-73, 2018201
33
2018
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR-mutation testing in NSCLC patients: a pooled analysis
F Passiglia, S Rizzo, C Rolfo, A Galvano, E Bronte, L Incorvaia, A Listi, ...Current Cancer Drug Targets 18 (7), 697-705, 2018201
31
2018

Referred From: https://scholar.google.com/citations?hl=en&user=6cuObdwAAAAJ

Cited by
Citations 19309
h-index 68
i10-index 260
Recommended Journals
Open Access Journals